Related Experiment Videos
Fluperlapine in 104 schizophrenic patients. Open multicenter trial
Arzneimittel-Forschung
|January 1, 1984
Summary
Fluprazine, an antipsychotic, demonstrated significant efficacy in treating schizophrenia, with 66% of patients showing good or very good benefit. Tolerability was high, with mild fatigue as the main side effect.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Trials
Background:
- Schizophrenia poses a significant challenge in mental health treatment.
- Novel antipsychotic agents are continuously sought to improve patient outcomes.
- Fluprazine (NB-106 689) is an investigational drug for schizophrenia.
Purpose of the Study:
- To evaluate the efficacy and tolerability of fluprazine in patients with acute or relapsed schizophrenia.
- To determine the optimal dosage and onset of action for fluprazine treatment.
Main Methods:
- Twelve parallel, open, uncontrolled therapeutic studies were conducted across multiple centers.
- Standardized protocols, case report forms, and assessment criteria were employed.
- Patient response was evaluated using Fischer Symptom Check List Neuroleptics (FSCL-NL) and Brief Psychiatric Rating Scale (BPRS).
Main Results:
- 66% of 104 patients achieved good or very good overall benefit, with an 80% responder rate.
- Fluprazine demonstrated a rapid onset of action, with 25% improvement in symptoms within 5 days.
- Tolerability was favorable in 88% of patients; mild fatigue was the most common side effect.
Conclusions:
- Fluprazine is an effective treatment for acute or relapsed schizophrenia, offering significant symptom improvement.
- The drug is generally well-tolerated, with a low incidence of severe adverse effects.
- Further investigation into fluprazine's safety profile, particularly regarding EEG abnormalities and rare hematological events, is warranted.